Optical coherence tomography assessment of axonal and neuronal damage of the retina in patients with familial and sporadic multiple sclerosis - Grudziecka Pyrek, M; Selmaj, K (medRxiv, 2022)
Objective Optical coherence tomography (OCT) assessment of axonal and neuronal damage of the retina in patients with familial and sporadic multiple sclerosis.Methods 45 patients with familial MS (fMS), 58 patients with sporadic MS (sMS) and 35 healthy controls were included in the study. OCT was performed with the spectral domain optical coherence tomography (SD-OCT, Heidelberg Engineering, Germany). The retinal nerve fiber layer (RNFL) thickness and macular volume (MV) were measured.Results A significant thinning of the global RNFL thickness was detected in both forms of MS compared to control group, (86,61 (+/- 14,74) µm in sMS, 85,8 (+/- 12,7) µm in fMS, 97,96 (+/- 7,6) µm in control group; p <0,001). There was no significant difference in the global RNFL thickness between sMS and fMS. A significant reduction of the MV was shown in sMS and fMS compared to control group (8,12 (+/- 1,14) mm3 in sMS, 8,1 (+/- 1,12) mm3 in fMS, and 8,81 (+/- 0,31) mm3 in control group; p = 0,003). No difference in MV between sMS and fMS was found. However, in eyes with history of optic neuritis (ON) MV was significantly reduced in sMS versus fMS (8,12 (+/- 2,87) mm3 vs. 8,42 (+/- 0,54) mm3; p=0,05).Conclusion We confirmed the presence of axonal and neuronal damage of the retina in sMS and fMS. ON induced a significantly greater reduction of MV in sMS compared to fMS, indicating a stronger neuronal damage in ON eyes in sMS than in fMS.KEY MESSAGES The familial MS accounts for a significant proportion of MS patients and there is still ongoing discussion on the distinction between familial (fMS) and sporadic (sMS) forms of this disease. Using OCT, we confirmed the presence of axonal and neuronal damage in the retina in both forms of MS. We found that optic neuritis (ON) induced a greater retinal neuronal damage in sMS than in fMS. These results support the conclusion that there are some discrete differences in pathological processes occurring in the retina in sMS and fMS.Competing Interest StatementCompeting interests MGP has nothing to report. KS has received personal compensation for consulting from Biogen, Celgene, GeNeuro, Merck, Novartis, Polpharma, Sanofi, Roche, TG Therapeutics, and received research support from Merck and Roche. Funding StatementFunding This study was supported by a grant PRELUDIUM from the National Science Center, Cracow, Poland, grant number UMO-2014/15/N/NZ4/01704Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Commission of the Medical University of Lodz, Poland (registration numbers: RNN/83/13/KE, RNN/178/16/KE).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript